Phathom Pharmaceuticals Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everyone. This is Yatin Suneja, one of the biotech analysts at Guggenheim. It is my pleasure to welcome Steven Basta, who is the President and Chief Executive Officer of Phathom. We will be chatting with him on all things happening at Phathom. Steven, thank you so much. Always a pleasure to chat with you and have you here at our conference. Why don't you make some opening comments, maybe review for us the third quarter of the financial performance and what are some of the upcoming milestones, and then we will maybe go into a little bit more deeper dive on some of the questions that I have prepared for you.
Terrific. Happy to do that. Yeah, thanks so much for the invitation to join you, and I appreciate the opportunity to update the team or the investors on what we are doing. Phathom, just for those of you who are new to this story, is commercializing VOQUEZNA, which is a meaningful improvement in the treatment of gastroesophageal reflux versus prior generation therapies. VOQUEZNA offers a patient who has been on a PPI and is still experiencing heartburn symptoms the opportunity to get relief from those symptoms by increasing pH in the stomach much more consistently and over a full 24-hour period as compared to prior PPI therapies. We launched the drug three years ago. In our third year of commercialization, we are guiding this year the full year revenues $310 million-$325 million, with meaningful growth over the $175 million that we did last year.
We are pleased to be on a significant growth path and on a clear path to having achieved positive cash flow for the first time over the last two quarters, and reaching a milestone that we had guided investors to, reaching operating profitability, excluding stock comp, but very close to operating profitability, even including stock comp in the recent quarter. That puts us on a path to continuing growth, but continuing growth profitably over the coming years, which is a meaningful advance in the company's overall financial trajectory. Fundamentally, we are launching a drug that is a meaningful improvement in treatment for patients in an enormous market opportunity in gastroesophageal reflux, with a really nice revenue ramp with financial discipline in our operations that is positioning the company to be a leader in the GI space.
Very good. Thank you for that. Then maybe perhaps double-clicking on the third quarter performance, pretty good performance. Just talk about what is driving the growth, what segments of the prescriber base you are able to penetrate now, where the penetrations look like, and how should we think about that growth trajectory as we go into Q4 and 2027? I understand you are not going to provide guidance, but qualitatively.
Right, qualitatively. One of the important things we did last year, as we reviewed the areas where we were getting the most traction, clearly the opportunity for us is first in GI, and then eventually will evolve into primary care. We really think about the market in those stages. What we did last year was we pivoted the commercial organization to focus on gastroenterology. We are now calling on virtually every gastroenterologist whose office we can get into. There are a few accounts, obviously, that you're not allowed to call on, but reaching the entire gastroenterology universe, including gastroenterologists and the associated APPs, nurse practitioners, PAs that are in those offices. That collectively represents about 24,000 total prescribers. We call on most of them. Most of them have prescribed VOQUEZNA, and 75% of our scripts are now coming out of that GI universe.
70% of our sales calls go into GI, 75% of our scripts come out of GI. That's the core growth engine for the company today. But we're not exclusively in GI. We're still making a significant percentage of our sales calls in primary care. We are seeing growth in primary care prescribers. Our growth is coming from two things: depth in GI, because already most of them are writing VOQUEZNA scripts, and expansion of the writer base to include more primary care prescribers. That's going to hold true for the next one to two years, where our core growth is going to be depth in GI, but the additional expansion into primary care new writers. Then we expect over time that primary care becomes an increasing portion of the business.
As we go deep in GI, part of the expansion that's going to happen is going to be the flow of patients back to primary care to get continued script, the continued education of primary care physicians. There's a fundamental inflection that I think is going to happen in 2029 with the as-needed use label.
Yep. As we get labeling for PRN use of VOQUEZNA, we're in the phase III trial today, that is going to open a conversation for physicians, both GIs and primary care physicians, with their patients around not just treating the most severe patients, but also patients who've been on daily PPI and haven't been adequately treated, or wish to not be on a daily therapy any longer.
Today, we're treating patients who haven't been adequately treated on a PPI. In the future, we expand not only that population, but also patients who just want to use a product as needed rather than being on chronic daily therapy. There are really two different market segments we can pursue.
Got it. I think you just mentioned these 24K GI writers, right?
Right. Can you put in perspective what level of scripts come out of these GIs?
I think in the past, you have talked about a couple million, and if you can penetrate a certain percentage, you can get to a billion dollars. Just maybe reframe that for us. What are those numbers, and where are you today?
Today, if you estimate, we did 380,000 prescriptions, TRX fills in Q3. Again, 75% of those are in GI.
Yes. 250,000-300,000 prescriptions coming out of GI.
That represents north of a 1 million prescription run rate out of a universe of PPI scripts that is 20 million PPI and H2 blocker scripts per year. We are reaching about 5% of that opportunity set in terms of that prescription base. If we get to 20%-25% or 30% penetration in that PPI prescribing volume, that is a billion dollars plus in revenue coming out of GI. Well, I mean, all of that totally makes sense if we are annualizing to north of a $300 million run rate today. You triple or 4X that revenue, and you get to that billion-dollar run rate. That is a clear path to a billion-dollar opportunity in GI, and we are a quarter of the way there.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
